A new randomized clinical trial shows that tocilizumab, a monoclonal antibody that inhibits IL-
6 signalling by binding to the IL-6 receptor, increases myocardial salvage in patients with …

Introduction Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and
myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 …

Background Prompt myocardial revascularization with percutaneous coronary intervention
(PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation …

It is well established that atherosclerosis is a prototypical chronic inflammatory disorder, and
there are several studies suggesting that persistent inflammation could also play an …

Background We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves
myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the …

Aim To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network
in patients with acute non-ST-elevation myocardial infarction (NSTEMI). Methods 117 …

Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-
elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we …

In the rapidly evolving story of inflammation and atherothrombosis, all roads seem to
converge on interleukin (IL)-6, a central signaling cytokine of innate immunity (1). More than …

Abstract Aims Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is
involved in myocardial injury during ischaemia–reperfusion. Interleukin-6 is therefore a …

Acute myocardial infarction (MI) occurs when blood supply falls below critical levels and
normal cellular maintenance mechanisms fail. Interleukin-6 (IL-6) is a proinflammatory …